Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
About
This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e. g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing.
The Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24) is a federal funding opportunity designed for research institutions capable of leading and managing a consortium-based research effort. This grant supports the establishment of a Research Coordinating Center that will harmonize multi-site clinical research on anti-obesity medication treatment strategies for youth with obesity. The RCC will oversee protocol development, standardize data collection and biospecimen handling, coordinate laboratory analyses, and facilitate collaborative manuscript development across participating clinical centers. Researchers should focus on evaluating optimal developmental stages for AOM initiation, dosing strategies, weight loss outcomes, medication classes, and the integration of adjunct lifestyle interventions. The grant emphasizes research that supports healthy growth and development, adequate nutrition, mental health outcomes, and quality of life while minimizing risks associated with long-term medication dependence. This opportunity is ideal for institutions with infrastructure, expertise in pediatric obesity research, clinical trial coordination capabilities, and commitment to understanding how anti-obesity medications can be safely and effectively implemented in real-world clinical settings for adolescent populations.
Funding Facts
● Applications openDeadline
October 9, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by funding cycle
Deadline
2026-10-09
Grant Type
federal
Application Cycle
Annual (Deadline: October 9, 2026)
Best For
Research institutions, academic medical centers, and health systems with pediatric obesity research expertise and multi-site clinical trial coordination capabilities
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Frequently Asked Questions
Who is eligible for Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)?
Eligible applicants must be U.S. domestic organizations. Foreign organizations and non-domestic components of U.S. organizations are not eligible. Non-U.S. entities and foreign components are not permitted. For complete eligibility requirements, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.
How much funding does Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed) provide?
Specific funding amounts are not listed in the available information. Funding varies by funding cycle. Applicants should consult the official NOFO for detailed information regarding budget limitations and funding expectations for the Research Coordinating Center role.
How do I apply for Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)?
Applications should be submitted according to the guidelines outlined in the NOFO. As a U24 award, this likely involves electronic submission through grants.nih.gov or eRA Commons. Applicants should carefully review all sections of the NOFO, including eligibility, application requirements, and review criteria. Contact the relevant NIH Institute or Center for additional guidance on submission procedures and technical assistance.
What can Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed) funding be used for?
Funding supports establishing and operating a Research Coordinating Center that will lead consortium activities including: protocol development and harmonization across clinical sites, implementation of common measures and standardized data collection procedures, management of central laboratory services and biospecimen collection, coordination of data analyses, and facilitation of multi-center manuscript development. The RCC will oversee research evaluating optimal AOM treatment strategies, developmental timing of medication initiation, dosing approaches, and integration of lifestyle interventions for pediatric obesity treatment.
Last updated: July 5, 2026